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Summary
Objective The prevalence of cardiovascular risk factors in
congenital adrenal hyperplasia (CAH) varies widely. In the light
of recent changes in treatment regimens, we have reassessed the
prevalence of these risk factors in our current cohort of patients
with CAH due to P450c21 deficiency.
Methods A retrospective cross-sectional study of 107 children
(39 M) with CAH aged 92 years (range 04–205 years). Anthro-
pometric, systolic (SBP) and diastolic (DBP) blood pressure data
were collected and expressed as standard deviation scores (SDS)
using UK growth reference data and the Fourth Task Force data
set, respectively. Fasting blood glucose with plasma insulin and
lipids was measured, and insulin resistance (HOMA IR) calcu-
lated using the homoeostasis assessment model.
Results 236% (33% men; 18% women) of the cohort were
obese (BMI SDS>2). BMI SDS was significantly higher
(P < 0001) when compared with the UK population. Nineteen
(209%) of 91 patients (20% men; 21% women) had systolic
hypertension and 8 [88% (86% men; 89% women)] had
diastolic hypertension. Mean SBP [108 (SD 135)] mm Hg was
significantly higher than the normal population (P < 0001), but
mean DBP was not (P = 007). Both SBP SDS and DBP SDS
were not related to BMI SDS. 95% of the subjects had hyperlip-
idaemia, but HOMA IR was more favourable compared with the
normal population.
Conclusion Despite a reduction in steroid doses over the last
decade, a number of children with CAH are still obese and
hypertensive. Whether this reflects general population trends or
indicates a need to further optimize treatment regimens remains
to be determined.
(Received 26 February 2013; returned for revision 26 March 2013;
finally revised 10 May 2013; accepted 4 June 2013)
Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive
disorder of adrenal steroid biosynthesis most commonly caused
by mutations or deletions in the CYP21A2 gene.1 This leads to a
variable deficiency of the enzyme 21-hydroxylase (P450c21) lead-
ing to a range of manifestations [salt-wasting type (SW CAH),
simple virilizing type (SV CAH), nonclassic type (NC CAH)].
Deficiency of P450c21 leads to decreased secretion of cortisol
and aldosterone with an increase in steroid precursors prior to
the block. Reduced cortisol stimulates adrenocorticotrophic hor-
mone secretion via negative feedback which then leads to adre-
nal hyperplasia and increased adrenal androgen production.2
These individuals also have decreased adrenal medullary func-
tion3 which has been suggested to lead to obesity and insu-
lin resistance (IR) via the leptin pathway.4 The treatment aim
in CAH is to replace the deficient hormones (glucocorticoid 
mineralocorticoid) and reduce the excessive androgens. The
management of CAH poses a great challenge as the therapeutic
window for glucocorticoids is narrow. Current treatment regi-
mens do not match the circadian rhythm often leading to poor
control of the disease despite the use of supraphysiological
doses.5,6
The combination of hyper/hypocortisolism, hyper/hypoan-
drogenism and adrenal medullary hypofunction due to the
disease and its treatment may make these individuals more
prone to develop cardiovascular risk factors such as obesity,
hypertension, IR and dyslipidaemia.7 Although treatment has
changed, the optimum method of delivery of steroids and
monitoring of treatment remains to be defined. Even with the
recent publication of guidelines,8 there are variations in dosage
schedules and methods of monitoring treatment across the
globe. This may explain the different prevalence rates reported
for cardiovascular risk factors in children and adults.9–15 Over
the last 10 years, we have modified our treatment regimen for
P450c21 deficiency in terms of glucocorticoid and mineralocor-
ticoid dosing and have undertaken an audit of practice to
reassess the prevalence of these cardiovascular risk factors in
our current cohort of patients with CAH due to P450c21
deficiency.
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Patients and methods
Patients
We undertook a retrospective analysis of the medical records of
all patients with CAH due to 21-hydroxylase deficiency who
were followed up in the Paediatric Endocrinology Department at
Great Ormond Street Hospital for Children between 2007 and
2012. The diagnosis of CAH P450c21 deficiency was based on
clinical and biochemical assessment and confirmed in all cases
by genetic analysis of the CYP21A2 gene. All patients were
treated with oral hydrocortisone (10–15 mg/m2/day) in three
or four divided doses. SW CAH was diagnosed in the presence
of hyponatraemia, hyperkalaemia, raised plasma renin activity
(PRA) and low plasma aldosterone concentrations. In addition
to hydrocortisone, these children received 9-alpha-fludrocorti-
sone (50–100 lg/m2/day) in one to two divided doses. Infants
with SW CAH also received sodium supplements (15–30 mEq/
kg/day) in four divided doses until their first birthday. In addi-
tion to regular clinic review 3–6 monthly, all underwent annual
reviews.
Methods
All patients with CAH had at least one detailed review per year.
Patients were admitted for 24 h. An intravenous cannula was
inserted, and plasma cortisol and 17-hydroxyprogesterone
(17-OHP) concentrations were measured as detailed in Table S1.
At 0800 h, a further sample was drawn for the measurement of
fasting blood glucose and plasma insulin, cholesterol and triglyc-
eride concentrations as well as plasma renin activity (PRA),
androstenedione (A4) and testosterone. Six hourly blood pressure
measurements were obtained using an oscillometric method
(Philips IntelliVue MP30, Germany) with appropriate size cuffs.
The average systolic (SBP) and diastolic blood pressures (DBP)
were derived from these measurements. Height was measured
using a Harpenden stadiometer (Holtain, Crymych, UK) and
weight using Seca digital weighing scale (Seca, Birmingham,
UK). Body mass index (BMI) was calculated using Quetelet
index (weight in kilograms/height in m2).
Hormone assays
Cortisol. Serum total cortisol was measured using competitive
chemiluminescent immunoassay (Immulite 2000 Siemens Diag-
nostics). The sensitivity of the assay is 55 nmol/l, and the
coefficients of variation (CV) were 11% and 4% at the levels
819 nmol/l and 499 nmol/l, respectively.
Plasma renin activity (PRA) was measured as described by
Menard & Catt.16 The assay sensitivity is 017 nmol/l/h, and the
CV is 49% at 049 nmol/l/h, 62% at 084 nmol/l/h and 79% at
137 nmol/l/h.
Cholesterol was measured using dry slide enzymatic (choles-
terol oxidase) method (Vitros 5600 Clinical Chemistry analyser,
Ortho Clinical Diagnostics). The sensitivity is 129 mmol/l with
a CV of 18% at 38 mmol/l. Triglycerides were measured using
this same method with the sensitivity of 011 mmol/l and a CV
of 14% at 135 mmol/l.
Glucose was measured using dry slide enzymatic (glucose
oxidase) method (Vitros 5600 Clinical Chemistry analyser, Ortho
Clinical Diagnostics). The assay sensitivity is 11 mmol/l, and the
CV is 15% at 46 mmol/l.
Insulin was measured using a two-site immunometric chemi-
luminescent immunoassay (Immulite 2000 Siemens Diagnostics).
The sensitivity is 2 mU/l with a CV of 177% at 39 mU/l and
39% at 189 mU/l.
Statistics
Anthropometric data were expressed as standard deviation
scores (SDS) using the 1990 UK growth reference data.17
Patients with BMI SDS >2 were classified as obese.18 The systolic
and diastolic blood pressures were expressed as percentiles and
SDS using the Fourth Task Force data set.19 For children
<1 year old, the normative values were taken from the Second
Task Force report.20 Patients with average SBP and/or DBP
≥95th percentile for gender, age and height were classified as
hypertensive and those between 90th and 95th centiles as prehy-
pertensive.19 IR was calculated using the homoeostasis model
assessment (HOMA) method and compared with a data set
from 94 short and tall normal individuals at Great Ormond
Street Hospital for Children. Fasting total plasma cholesterol
concentrations >55 mmol/l and fasting plasma triglyceride
concentrations >155 mmol/l were considered to be elevated.
Statistical analysis was performed using SPSS version 21. Non-
normally distributed data were logarithmically transformed prior
to analysis. Normally distributed data are expressed as mean and
SD, whereas non-normally distributed data were expressed
as median and interquartile range (IQR). Mean data were
compared between groups using Student’s t-test. When more
than two groups were compared, one-way analysis of variance
(ANOVA) with Tukey’s post hoc test was used to determine signifi-
cance. Stepwise multiple linear regression analysis was used to
explore relationships between blood pressure and chronological
age, steroid doses, BMI SDS and mean cortisol concentration.
A P-value <005 was considered as depicting significance.
Results
General characteristics
The records of 107 patients (39 men), aged 04–205 years
(median 92 years) were analysed. Of these, 57 (533%) patients
were in the age group 0–99 years, 37 (346%) in the age group
10–149 years and 13 (121%) were in the age group ≥15 years.
Seventy-nine (74%) patients had SW CAH, and the remainder
had SV CAH. Table 1 shows the biochemical parameters of
control in the patients. With the current regimens, the overall
biochemical control was inadequate with high premorning dose
17-OHP concentrations and increased mean 24 h 17-OHP
concentrations. Forty-four (63%) of 70 patients had high plasma
androstenedione concentrations, and only 23 (33%) had normal
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levels and 3 (4%) had low levels. Mean PRA was <10 pmol/ml/
h, suggesting adequate mineralocorticoid replacement.
Steroid doses
Mean daily hydrocortisone and 9-alpha-fludrocortisone replace-
ment doses were 133 (SD 44) mg/m2 body surface area (BSA)
and 102 (SD 50) lg/m2 BSA, respectively. These doses varied
depending upon age: mean hydrocortisone and 9-alpha-fludro-
cortisone doses were 133 (SD 49) mg/m2 BSA and 1214 (SD
515) lg/m2 BSA, respectively, in the 0-99 years age group, 13
(SD 35) mg/m2 BSA and 84 (SD 397) lg/m2 BSA, respectively,
in the 10–149 years age group and 14 (SD 45) mg/m2 BSA and
67 (SD 277) lg/m2 BSA, respectively, in the ≥15 years age
group (Table 1). There was no relationship between hydrocorti-
sone dose and age, whereas the dose of 9-alpha-fludrocortisone
was negatively correlated with age (r = 06; P = 0000) in both
sexes [Fig. 1(a)].
Obesity
Table 2 shows the anthropometric data in 106 patients in the
different age groups. Twenty-five (236%) of 106 subjects (33%
of men, 178% of women; v2 = 007, P = 009) in the cohort
were obese. In the whole study group, weight SDS and BMI SDS
were significantly higher (P < 0001) in both sexes when com-
pared with the UK population mean. Height SDS was similar to
the patient’s mid-parental height SDS and the reference popula-
tion except in the older age group (≥15 years group) who were
significantly shorter (P = 001). There were significant positive
correlation of weight SDS (r = 0327; P = 0001) and BMI SDS
with age (r = 0368, P < 0001) [Fig. 1(b)], but this trend was
not seen with height SDS irrespective of sex. BMI SDS was not
related significantly to hydrocortisone dose (r = 017; P = 007)
but was negatively related to fludrocortisone dose (r = 038,
P < 0001).
Hypertension
The average SBP in 91 patients with CAH is shown in Fig. 2(a).
Nineteen (209%) of 91 patients (20% men; 21% women) had
systolic hypertension and 10 (11%) patients were noted to have
prehypertension. Mean SBP [108 (SD 135) mm Hg] and mean
SBP SDS 076 (SD 119) were significantly higher than the refer-
ence population (P < 0001). There was a significant negative
relationship between SBP SDS and age (r = 033; P = 004)
but only in men.
The average DBP in 91 subjects is shown in Fig. 2(b). Eight
(88%) of 91 patients (86% men; 89% women) had diastolic
hypertension with no difference between sexes. Mean DBP [59
(SD 108) mm Hg] and mean DBP SDS 019 (SD 101) were
not significantly higher than the reference population (P = 007).
DBP SDS was negatively related to age (r = 03; P = 002) in
women only. Only 3 (33%) patients had both systolic and
diastolic hypertension.
Factors influencing blood pressure
The relationship between systolic and diastolic blood pressure
was explored using stepwise multiple linear regression analysis.
SBP SDS was predicted only by CA (adjusted r2 = 009;
P = 0008), and DBP SDS was predicted by mean plasma corti-
sol and 9-alpha-fludrocortisone dose (adjusted r2 = 022;
P = 0000). Neither SBP SDS nor DBP SDS was significantly
related to BMI SDS (r = 011, P = 028; r = 01, P = 036,
respectively).
Insulin resistance
The difference in the insulin–glucose status between the normal
and CAH individuals is shown in Table 3. Fasting blood glucose,
fasting plasma insulin and HOMA IR in the CAH subjects were
lower than the normal individuals. HOMA IR was positively
related to age (r = 028; P = 003) but not to BMI SDS
(r = 015; P = 026).
Hyperlipidaemia
Of 63 subjects, 6 (95%) had high plasma triglycerides concen-
trations and 2 (3%) had high plasma cholesterol concentrations
with no differences between sexes. These were not related to age,
BMI SDS, blood pressure and hydrocortisone dose.
Table 1. Steroid doses and biochemical markers of control
Age groups
Hydrocortisone
(mg/m2)
Mean (SD)
Fludrocortisone
(lg/m2)
Mean (SD)
Mean 17-OHP
(nmol/l)
Median (IQR)
Mean cortisol
(nmol/l)
Median (IQR)
Androstenedione
(lmol/l)
Median (IQR)
Plasma renin activity
(nmol/h/l)
Median (IQR)
0–99 years 133 (49) 1214 (515) n = 54
27 (6–80)
n = 55
187 (151–214)
n = 32
27 (1–127)
n = 50
57 (27–94)
10–149 years 13 (35) 84 (397) n = 32
56 (18–132)
n = 35
175 (144–200)
n = 28
139 (68–288)
n = 27
39 (23–65)
≥15 years 14 (45) 67 (277) n = 13
61 (9–149)
n = 11
203 (154–223)
n = 10
159 (52–215)
n = 11
36 (2–57)
All age 133 (44) 102 (50) n = 99
38 (8–123)
n = 101
184 (151–210)
n = 70
93 (2–19)
n = 88
5 (24–72)
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Comparison of salt-wasting and simple virilizing types of
CAH
There was no significant difference in the age and sex distribution
between the SW and SV CAH groups at the time of analysis.
Table 4 shows the anthropometric data between the SW and the
SV types. The height SDS and weight SDS of SV CAH subjects
were significantly higher compared with the SW CAH subjects
(P < 0001 for both). There was no significant difference in the
prevalence of hypertension, insulin resistance and hyperlipidaemia
between these two groups.
Discussion
These data demonstrate that obesity and hypertension remain
problem areas in children with CAH. Compared with our previ-
ous data, there has been a reduction in the numbers who are
obese and hypertensive, which probably reflects the lower dosing
schedules used since the last publication.9 The mean hydrocorti-
sone (133 mg/m2) and 9-alpha-fludrocortisone (102 lg/m2)
doses are similar to the recommended doses in the Endocrine
Society Practice Guidelines.8 Of note, there was a significant
negative correlation between the 9-alpha-fludrocortisone dose
and the age which reflects our clinical practice not to increase
the mineralocorticoid dose on a body size basis once a maximum
of 100 micrograms per day has been reached.
Obesity is an independent risk factor for CVD,21 and the
prevalence in the general population varies and is increasing
across the globe.22 This has an impact on the prevalence of
obesity among CAH subjects and could partly explain the varied
prevalence of obesity in different studies along with the disease
and treatment factors. The prevalence of obesity in our cohort
was 236% (33% men; 178% women) which is higher than that
reported in the Health Survey for England 201022 (171% men;
148% women). However, men with CAH have a significantly
higher risk of obesity than women when compared with the
normal population. In other studies in children with CAH, the
prevalence of obesity has been reported as 35%15 and 168%10.
The mean BMI SDS in our cohort was significantly less (098 vs
157) compared with our previous report a decade ago.9 While
the prevalence of obesity in general population is increasing, the
most likely explanation for this significant decrease in BMI SDS
could be due to effect of change in the management of these
patients. Interestingly, the mean hydrocortisone dose used in
our previous study9 was significantly higher (175 vs 133 mg/
m2), and this may have played an important role in the reduc-
tion in the BMI SDS. A more variable prevalence of obesity was
reported in adults with CAH, but this may reflect the higher
dosing regimens used in the 1970 and 1980s.11,12,15 However, we
Table 2. Anthropometric data
Age groups (n)
Height SDS
Mean (SD) P-value
Delta height SDS
Mean (SD) P-value
Weight SDS
Mean (SD) P-value
BMI SDS
Mean (SD) P-value
0–99 years (56) 011 (166) 0623 016 (15) 0494 027 (178) 0261 06 (149) 0004*
10–149 years (37) 008 (168) 0769 007 (184) 0849 111 (137) <0001* 143 (12) <0001*
15 years and above (13) 09 (114) 0014* 103 (13) 0037* 069 (137) 096 134 (131) 0003*
All age group (106) 002 (163) 088 019 (16) 0297 061 (164) <0001* 098 (142) <0001*
Delta Height SDS, Height SDS-Target Ht SDS.
*P-value<005, significant.
(a)
(b)
Fig. 1 (a) Correlation between chronological age and 9-alpha-
fludrocortisone dose. (b) Correlation between age and BMI SDS.
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could not find a significant correlation between the steroid doses
and BMI SDS in the current study, and this could be due to
small variance in doses used as they are calculated on the basis
of body size. BMI is not an accurate estimate of body fat partic-
ularly in CAH where androgen effects on muscle mass may be
important. Consideration should be given in future studies to
the use of dual-energy X-ray absorptiometry to estimate body
composition.
The mean height SDS in this cohort was similar to the popu-
lation mean and the mid-parental SDS in the under 15 year age
group indicating optimum growth with current doses of steroids
used. However, the mean height SDS was lower in the over
15 year age group and was similar to the adult height reported
in the recent meta-analysis.23 This might reflect the previous
management strategies using higher doses of steroids compared
with the current dosage schedule. Although similar trend is seen
when compared with target height SDS, we did not have full
data on bone age to compare.
The prevalence of hypertension varies widely between studies.
The prevalence of systolic (209% vs 58%) and diastolic hyper-
tension (88% vs 24%) was significantly less when compared
with our previous study but still higher than the population
mean.9,24 This may reflect the lower steroid doses used in our
patients compared with our previous study9 (mean hydrocortisone
(a)
(b)
Fig. 2 (a) Systolic blood pressure in CAH.
(b) Diastolic blood pressure in CAH.
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dose 133 vs 175 mg/m2 and the mean 9-alpha-fludrocortisone
dose 102 vs 112 lg/m2. Interestingly in another study in the
paediatric age group, the prevalence of systolic hypertension was
only 11% and CAH individuals with normal weight even showed
diastolic hypotension.24 This might be due to the use of even
lower doses of 9-alpha-fludrocortisone compared with our study
(mean dose 48 vs 102 lg/m2). In a recent study15, the prevalence
of hypertension was even higher than our current study even
though the mean hydrocortisone dose used was similar to our
study. These differences may relate in part to the dosing as sug-
gested but may also be influenced by the methods for recording
blood pressure. We aimed to obtain standardized blood pressure
measurements over a 24-h period to avoid, where possible, the
possibility of ‘white coat hypertension’. Both SBP SDS and DBP
SDS were negatively related to age, and this might be due to
reduction in the dose of fludrocortisone, on a body size basis, as
age advances. This might also explain why the prevalence of
hypertension in the adult CAH population is not as high as that
seen in paediatric reports.12,15 Blood pressure was not related to
BMI, in contrast to previous studies9,24 suggesting that the treat-
ment regimen remains an important factor in generating high
BP. The true prevalence of hypertension in our study might be
even lower as we used the oscillometric method that tends to
overestimate blood pressure by few mmHg compared with
sphygmomanometer recordings.25
HOMA IR in our CAH cohort was lower than our historical
controls, in contrast to previous studies where it was signifi-
cantly higher.4,15 This might again be due to the difference in
the steroid doses, the taking of samples early morning before the
hydrocortisone dose and the difference in the BMI SDS noted
between these studies. HOMA IR was also not related to BMI
SDS or BP in contrast to the above studies. Although there was
a slight increase (95%) in the prevalence of hyperlipidaemia in
our cohort, we did not have proper controls to assess the signifi-
cance. Variable reports both in adults and children exist, some
showing an increased prevalence12,15 and others not. 13 Some
studies even show that the prevalence of dyslipidaemia is less in
CAH patients compared with the general population.11,14 How-
ever, patients with positive family history of dyslipidaemia
should have further investigations to rule out familial hypercho-
lesterolaemia.
One of the limitations of our study is that the full data set
was not complete in all patients. We also did not evaluate other
risk factors such as serum adiponectin, CRP, homocysteine and
arterial intima-media thickness.26,27 However, it is very encour-
aging to see the decreasing trend in the prevalence of the cardio-
vascular risk factors in our children with CAH most likely
attributed to significant reduction in hydrocortisone and fludro-
cortisone doses over the last decade. Several individuals are
obese, and BMI SDS tends to be higher than average. With the
availability of more physiological modalities, such as subcutane-
ous pumps28 or sustained release preparations,29 ongoing audit
of cardiovascular risk factors is warranted. Assessments such as
these should be incorporated into a best practice quality assur-
ance scheme for patients with CAH.
Acknowledgements
This study was supported by the Audit Office of Great Ormond
Street Hospital for Children.
Conflicting interest
Nothing to declare.
References
1 White, P.C., New, M.I. & Dupont, B. (1984) HLA-linked con-
genital adrenal hyperplasia results from a defective gene encoding
a cytochrome P-450 specific for steroid 21-hydroxylation. Pro-
ceedings of the National Academy of Sciences of the United States
of America, 81, 7505–7509.
2 White, P.C. & Speiser, P.W. (2000) Congenital adrenal hyperpla-
sia due to 21-hydroxylase deficiency. Endocrine Reviews, 21, 245–
291.
3 Merke, D.P., Chrousos, G.P., Eisenhofer, G. et al. (2000)
Adrenomedullary dysplasia and hypofunction in patients with
classic 21-hydroxylase deficiency. New England Journal of Medi-
cine, 343, 1362–1368.
4 Charmandari, E., Weise, M., Bornstein, S.R. et al. (2002) Chil-
dren with classic congenital adrenal hyperplasia have elevated
serum leptin concentrations and insulin resistance: potential clin-
ical implications. Journal of Clinical Endocrinology and Metabo-
lism, 87, 2114–2120.
5 Charmandari, E., Johnston, A., Brook, C.G. et al. (2001) Bio-
availability of oral hydrocortisone in patients with congenital
Table 3. Insulin–glucose status between CAH and normal individuals
Age <10 years
Normal (n = 56)
Mean (SD)
CAH (n = 25)
Mean (SD) P-value
Fasting glucose 46 (05) 41 (06) <0001*
Fasting insulin 10 (8) 5 (38) 0002*
HOMA IR 13 (09) 07 (04) 0001*
HOMA%B 132 (66) 104 (43) 0048*
Age ≥10 years Normal (n = 38)
Mean (SD)
CAH (n = 32)
Mean (SD)
P-value
Fasting glucose 46 (06) 44 (04) 007
Fasting insulin 114 (63) 89 (46) 007
HOMA IR 14 (08) 11 (06) 005
HOMA%B 148 (72) 132 (44) 0288
*P = <005, significant.
Table 4. Anthropometric data of SW CAH vs SV CAH
SW CAH (n = 78)
Mean (SD)
SV CAH (n = 28)
Mean (SD) P-value
Height SDS 042 (143) 109 (166) <0001*
Weight SDS 034 (165) 138 (135) 0003*
BMI SDS 087 (15) 128 (114) 0199
*P-value<005, significant.
© 2013 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Clinical Endocrinology (2014), 80, 471–477
476 A. Subbarayan et al.
adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of
Endocrinology, 169, 65–70.
6 Charmandari, E., Hindmarsh, P.C., Johnston, A. et al. (2001)
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency:
alterations in cortisol pharmacokinetics at puberty. Journal of
Clinical Endocrinology and Metabolism, 86, 2701–2708.
7 Falhammar, H. & Thoren, M. (2012) Clinical outcomes in the
management of congenital adrenal hyperplasia. Endocrine, 41,
355–373.
8 Speiser, P.W., Azziz, R., Baskin, L.S. et al. (2010) Congenital
adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an
Endocrine Society clinical practice guideline. Journal of Clinical
Endocrinology and Metabolism, 95, 4133–4160.
9 Roche, E.F., Charmandari, E., Dattani, M.T. et al. (2003) Blood
pressure in children and adolescents with congenital adrenal
hyperplasia (21-hydroxylase deficiency): a preliminary report.
Clinical Endocrinology (Oxf), 58, 589–596.
10 V€olkl, T.M., Simm, D., Beier, C. et al. (2006) Obesity among chil-
dren and adolescents with classic congenital adrenal hyperplasia
due to 21-hydroxylase deficiency. Pediatrics, 117, e98–e105.
11 Falhammar, H., Filipsson, H., Holmdahl, G. et al. (2007) Meta-
bolic profile and body composition in adult women with con-
genital adrenal hyperplasia due to 21-hydroxylase deficiency.
Journal of Clinical Endocrinology and Metabolism, 92, 110–116.
12 Arlt, W., Willis, D.S., Wild, S.H., (CaHASE), et al. (2010) Health
status of adults with congenital adrenal hyperplasia: a cohort
study of 203 patients. Journal of Clinical Endocrinology and
Metabolism, 95, 5110–5121.
13 Falhammar, H., Filipsson Nystr€om, H., Wedell, A. et al. (2011)
Cardiovascular risk, metabolic profile, and body composition in
adult males with congenital adrenal hyperplasia due to 21-
hydroxylase deficiency. European Journal of Endocrinology, 164,
285–293.
14 Mooij, C.F., Kroese, J.M., Sweep, F.C. et al. (2011) Adult
patients with congenital adrenal hyperplasia have elevated blood
pressure but otherwise a normal cardiovascular risk profile. PLoS
ONE, 6, e24204.
15 Finkielstain, G.P., Kim, M.S., Sinaii, N. et al. (2012) Clinical
characteristics of a cohort of 244 patients with congenital adrenal
hyperplasia. Journal of Clinical Endocrinology and Metabolism, 97,
4429–4438.
16 Menard, J. & Catt, K.J. (1972) Measurement of renin activity,
concentration and substrate in rat plasma by radioimmunoassay
of angiotensin I. Endocrinology, 90, 422–430.
17 Freeman, J.V., Cole, T.J., Chinn, S. et al. (1995) Cross sectional
stature and weight reference curves for the UK, 1990. Archives of
Disease in Childhood, 73, 17–24.
18 Wabitsch, M. (2000) Obesity in childhood and adolescence: rec-
ommendations of a United States of America Task Force for
diagnosis and therapy. Klinische Padiatrie, 212, 287–296.
19 National High Blood Pressure Education Program Working
Group on High Blood Pressure in Children and, Adolescents.
(2004) The fourth report on the diagnosis, evaluation, and
treatment of high blood pressure in children and adolescents.
Pediatrics, 114(2 Suppl 4th Report), 555–576.
20 Report of the Second Task Force on Blood Pressure Control in
Children. (1987) Task Force on Blood Pressure Control in Chil-
dren. National Heart, Lung, and Blood Institute, Bethesda,
Maryland. Pediatrics, 79, 1–25.
21 Hubert, H.B., Feinleib, M., McNamara, P.M. et al. (1983) Obes-
ity as an independent risk factor for cardiovascular disease: a 26-
year follow-up of participants in the Framingham Heart Study.
Circulation, 67, 968–977.
22 Craig, R. & Mindell, J. eds. (2011) Health survey for England
2010. NHS Information Centre, London.
23 Muthusamy, K., Elamin, M.B., Smushkin, G. et al. (2010) Clini-
cal review: adult height in patients with congenital adrenal
hyperplasia: a systematic review and metaanalysis. Journal of
Clinical Endocrinology and Metabolism, 95, 4161–4172.
24 V€olkl, T.M., Simm, D., D€otsch, J. et al. (2006) Altered 24-hour
blood pressure profiles in children and adolescents with classical
congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Journal of Clinical Endocrinology and Metabolism, 91, 4888–4895.
25 Barker, M.E., Shiell, A.W. & Law, C.M. (2000) Evaluation of the
Dinamap 8100 and Omron M1 blood pressure monitors for use
in children. Paediatric and Perinatal Epidemiology, 14, 179–186.
26 V€olkl, T.M., Simm, D., Korner, A. et al. (2009) Adiponectin lev-
els are high in children with classic congenital adrenal hyperpla-
sia (CAH) due to 21-hydroxylase deficiency. Acta Paediatrica, 98,
885–891.
27 Sartorato, P., Zulian, E., Benedini, S. et al. (2007) Cardiovascular
risk factors and ultrasound evaluation of intima-media thickness
at common carotids, carotid bulbs, and femoral and abdominal
aorta arteries in patients with classic congenital adrenal hyper-
plasia due to 21-hydroxylase deficiency. Journal of Clinical Endo-
crinology and Metabolism, 92, 1015–1018.
28 Bryan, S.M., Honour, J.W. & Hindmarsh, P.C. (2009) Manage-
ment of altered hydrocortisone pharmacokinetics in a boy with
congenital adrenal hyperplasia using a continuous subcutaneous
hydrocortisone infusion. Journal of Clinical Endocrinology and
Metabolism, 94, 3477–3480.
29 Verma, S., Vanryzin, C., Sinaii, N. et al. (2010) A pharmacokinetic
and pharmacodynamic study of delayed- and extended-release
hydrocortisone (Chronocort) vs. conventional hydrocortisone
(Cortef) in the treatment of congenital adrenal hyperplasia.
Clinical Endocrinology (Oxf), 72, 441–447.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Table S1. Annual review programme for children and young
people with congenital adrenal hyperplasia.
© 2013 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Clinical Endocrinology (2014), 80, 471–477
Cardiovascular risk factors in children with congenital adrenal hyperplasia 477
